Background: An increased incidence of ultraviolet-light-related skin tumours is a well-known problem in patients undergoing posttransplantation immunosuppression with systemic calcineurin inhibitors such as cyclosporine A or tacrolimus. UV-related carcinogenesis as a consequence of long-term treatment of sun-exposed sites with topical calcineurin inhibitors is therefore of theoretical concern. Results: In this study, we show that tacrolimus acts as a UVB filter when incorporated into liposome membranes. In hairless mice pretreated with 1% pimecrolimus cream, 0.1% tacrolimus ointment or vehicle, the amount of epidermal thymine dimers, measured 1 h after 1 J/cm2 of UVB irradiation, was decreased by 89, 84 and 47%, respectively, as compared to untreated mice. Forty-eight hours after UVB irradiation, 97, 89 and 93% of epidermal thymine dimer levels were removed in pimecrolimus-, tacrolimus- or vehicle-treated mice, respectively. In contrast, 69% of thymine dimers, originally present in much higher amounts than in treated mice, were removed from untreated controls. UVB-induced apoptosis was less pronounced in treated mice. Conclusion: Taken together, these results suggest that topical calcineurin inhibitors prevent DNA photodamage due to a filter effect of both vehicle and active components, whereas they do not affect the clearance of DNA photoproducts.

1.
Gupta AK, Chow M: Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003;17:493–503.
2.
Robinson N, Singri P, Gordon KB: Safety of the new macrolide immunomodulators. Semin Cutan Med Surg 2001;20:242–249.
3.
Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365–372.
4.
Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, Autio P, Lauerma AI: Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;111:396–398.
5.
Lindelof B, Sigurgeirsson B, Gabel H, Stern RS: Incidence of skin cancer in 5,356 patients following organ transplantation. Br J Dermatol 2000;143:513–519.
6.
Bieber T: Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998;102:555–557.
7.
Tran C, Sorg O, Carraux P, Didierjean J, Siegenthaler G, Falson F, Saurat JH: A new model using liposomes that allow to distinguish between absorption and oxidative properties of sunscreens. Photochem Photobiol 2002;75:1–5.
8.
Antille C, Tran C, Sorg O, Carraux P, Didierjean J, Saurat JH: Vitamin A exerts a photoprotective action in skin by absorbing UVB radiations. J Invest Dermatol 2003;121:1163–1167.
9.
Sorg O, Tran C, Carraux P, Didierjean L, Saurat JH: Retinol and retinyl ester epidermal pools are not identically sensitive to UVB irradiation and antioxidant protective effect. Dermatology 1999;199:302–307.
10.
Tuteja N, Tuteja R: Unraveling DNA repair in human: molecular mechanisms and consequences of repair defect. Crit Rev Biochem Mol Biol 2001;36:261–290.
11.
Anslinger K, Bayer B, Rolf B, Keil W, Eisenmenger W: Application of the Biorobot EZ1 in a forensic laboratory. Leg Med (Tokyo) 2005;7:164–168.
12.
Smit NP, Vink AA, Kolb RM, Steenwinkel MJ, van den Berg PT, van Nieuwpoort F, Roza L, Pavel S: Melanin offers protection against induction of cyclobutane pyrimidine dimers and 6–4 photoproducts by UVB in cultured human melanocytes. Photochem Photobiol 2001;74:424–430.
13.
Okamoto H, Mizuno K, Itoh T, Tanaka K, Horio T: Evaluation of apoptotic cells induced by ultraviolet light B radiation in epidermal sheets stained by the TUNEL technique. J Invest Dermatol 1999;113:802–807.
14.
Lu YP, Lou YR, Yen P, Mitchell D, Huang MT, Conney AH: Time course for early adaptive responses to ultraviolet B light in the epidermis of SKH-1 mice. Cancer Res 1999;59:4591–4602.
15.
Vink AA, Berg RJ, de Gruijl FR, Lohman PH, Roza L, Baan RA: Detection of thymine dimers in suprabasal and basal cells of chronically UVB-exposed hairless mice. J Invest Dermatol 1993;100:795–799.
16.
Matsumura Y, Ananthaswamy HN: Molecular mechanisms of photocarcinogenesis. Front Biosci 2002;7:d765–d783.
17.
Schuler M, Green DR: Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001;29:684–688.
18.
Chiarugi A: Poly(ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisited. Trends Pharmacol Sci 2002;23:122–129.
19.
Schwarz A, Stander S, Berneburg M, Bohm M, Kulms D, van Steeg H, Grosse-Heitmeyer K, Krutmann J, Schwarz T: Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 2002;4:26–31.
20.
Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D, Malachi T, Gafter U: Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001;137:14–20.
21.
Fruman DA, Klee CB, Bierer BE, Burakoff SJ: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992;89:3686–3690.
22.
Herman M, Ori Y, Chagnac A, Weinstein T, Korzets A, Zevin D, Malachi T, Gafter U: DNA repair in mononuclear cells: role of serine/threonine phosphatases. J Lab Clin Med 2002;140:255–262.
23.
Ahlers C, Kreideweiss S, Nordheim A, Ruhlmann A: Cyclosporin A inhibits Ca2+-mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells. Eur J Biochem 1999;264:952–959.
24.
Billich A, Aschauer H, Aszodi A, Stuetz A: Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29–35.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.